This session is a basic introduction to cancer treatments and their most common side effects and adverse reactions. The course provides an overview on cancer surgery, radiotherapy and chemotherapy we well as insights on the mechanisms of action of targeted therapies such as monoclonal antibodies, small inhibitory molecules, CAR-T cell therapy and immune checkpoint inhibitors.

In the second part of the session, participants will learn about the mechanisms of toxicity linked to the different categories of cancer therapy and how these are managed.

This course is not recommended for clinicians.

This course runs from 10:00am until 13.00pm.

CAR-T Cell Therapy In Cancer Clinical Trials Manufacturing Regulations & Clinical Implementation.

This course offers a thorough exploration of CAR-T cell therapies (Chimeric Antigen Receptor T cell) within the realm of clinical trials. Participants will delve into the historical background of CAR-T therapies, their classifications, regulatory frameworks, safety considerations, mechanisms of action. Additionally, the course emphasizes Good Manufacturing Practice (GMP), addressing essential considerations, manufacturing processes, and quality control. By the end of the course, participants will have a solid understanding of CAR-T therapies in the context of clinical trials, including practical insights into managing CAR-T cell therapy trials and an overview of their clinical implementation.

This session gives a comprehensive overview of the clinical pathways cancer patients can take to be eventually referred for trial entry. The first part of the session spans across the diagnostic methods and staging of cancer and gives a brief overview of the common tests carried out prior to trial treatment.

In the second part of the session participants will learn about the importance of ensuring only eligible patients enter a trial and how eligibility criteria help to safeguard patients and differ amongst different phases of trials. They will also learn the importance of assessing treatment compliance and how every clinical intervention comes with a different set of challenges in collecting data about patient compliance.

This session, aimed at non-statisticians, will cover the most common primary outcomes measures used in early and late phase cancer trials.

Learning Outcomes:

Participants will learn what makes a good outcome measure, how outcomes measures are defined and what data need to be collected to assess the outcome, especially for tumour response assessment and time to event measures such as survival and disease (or progression) free survival.

This course runs from 10:00am until 13.00pm

1-day, in-person course

This course will provide an overview of how QoL is used in research studies, covering how to:

• select appropriate QoL instruments for a study
• outline QoL measures in protocols and grant applications
• analyse and properly interpret QoL data

Examples from a range of medical areas would be used, such as cancer, immunology, and paediatric and chronic disorders. Attendees can understand some of the common core principles but also differences in applying QoL between disorders. The course will also outline how QoL is used in decision-making to support implementing new interventions into clinical practice such as market authorisation and market access of new drugs. Sessions will be interactive and based on real-life examples.

Target Audience:

This course is for healthcare professionals, including researchers, clinicians, and statisticians from universities, NHS and pharmaceutical companies. No prior knowledge of quality of life is required.

Times 09.00 to 17.00